Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3
Executive Summary
Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.
You may also be interested in...
Sanofi Overcomes Zantac Troubles To Gain Share In US
Sanofi Consumer Healthcare has been gaining share in the US OTC market since October 2020 after putting behind it long running Zantac troubles, according to business head Julie Van Ongevalle.
Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
FDA Finds Ranitidine Poses Little Risk, But Concerns Linger
Ranitidine no more carcinogenic than grilled meat, says FDA drug center director Janet Woodcock. Agency finds NDMA levels in ranitidine drugs well below those claimed by Valisure, online pharmacy asking FDA to order drug off US market.